Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Laurie Gaspar

Concepts (490)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Brain Neoplasms
101
2025
1322
6.010
 Why?
Lung Neoplasms
92
2025
2645
4.920
 Why?
Carcinoma, Non-Small-Cell Lung
54
2022
1183
3.860
 Why?
Radiosurgery
44
2022
398
3.630
 Why?
Cranial Irradiation
21
2025
85
2.800
 Why?
Small Cell Lung Carcinoma
12
2025
121
2.620
 Why?
Combined Modality Therapy
62
2022
1267
1.190
 Why?
Radiation Pneumonitis
5
2021
31
1.170
 Why?
Radiotherapy, Intensity-Modulated
9
2018
141
1.140
 Why?
Carcinoma, Small Cell
8
2007
174
1.070
 Why?
Antineoplastic Combined Chemotherapy Protocols
30
2023
1967
1.030
 Why?
Neoplasm Staging
39
2020
1471
1.010
 Why?
Radiotherapy Dosage
39
2023
288
0.990
 Why?
Chemoradiotherapy
8
2020
237
0.950
 Why?
Practice Guidelines as Topic
11
2021
1531
0.940
 Why?
Brachytherapy
12
2017
133
0.880
 Why?
Radiotherapy Planning, Computer-Assisted
11
2021
149
0.850
 Why?
Radiation Oncology
12
2022
87
0.820
 Why?
Glioblastoma
18
2016
354
0.810
 Why?
Neoplasm Recurrence, Local
21
2017
1147
0.790
 Why?
Adenocarcinoma
13
2022
936
0.680
 Why?
Glioma
15
2015
429
0.680
 Why?
Aged
103
2025
25822
0.650
 Why?
Esophageal Neoplasms
9
2008
347
0.650
 Why?
Survival Rate
31
2018
2051
0.650
 Why?
Liver Neoplasms
8
2009
782
0.640
 Why?
Prognosis
45
2022
4253
0.640
 Why?
Humans
222
2025
144857
0.640
 Why?
Radiotherapy, Conformal
8
2017
74
0.630
 Why?
Radiotherapy
14
2017
209
0.610
 Why?
Clinical Trials as Topic
18
2018
1054
0.600
 Why?
Radiotherapy, Adjuvant
16
2022
222
0.600
 Why?
Middle Aged
119
2025
35939
0.600
 Why?
Neurosurgeons
1
2019
17
0.590
 Why?
Evidence-Based Medicine
10
2021
711
0.580
 Why?
Dacarbazine
9
2016
100
0.580
 Why?
Four-Dimensional Computed Tomography
6
2021
38
0.560
 Why?
Oncologists
1
2018
46
0.520
 Why?
Patient Selection
10
2019
699
0.510
 Why?
Carcinoma, Squamous Cell
10
2017
649
0.500
 Why?
Clinical Decision-Making
3
2021
353
0.490
 Why?
Cisplatin
18
2021
338
0.480
 Why?
Male
129
2025
72189
0.480
 Why?
Physician's Role
1
2018
218
0.480
 Why?
Aged, 80 and over
45
2020
8185
0.480
 Why?
Antineoplastic Agents, Alkylating
8
2016
72
0.470
 Why?
Female
132
2025
78217
0.460
 Why?
Antineoplastic Agents
20
2017
2224
0.460
 Why?
Induction Chemotherapy
2
2013
87
0.430
 Why?
Adult
91
2025
40438
0.410
 Why?
Receptor Protein-Tyrosine Kinases
5
2017
231
0.410
 Why?
Survival Analysis
24
2020
1362
0.400
 Why?
Physician-Patient Relations
1
2018
588
0.380
 Why?
Treatment Outcome
36
2021
11581
0.380
 Why?
Etoposide
12
2021
167
0.370
 Why?
Pro-Opiomelanocortin
7
1989
20
0.360
 Why?
Pneumonectomy
2
2015
169
0.340
 Why?
Astrocytoma
9
2014
130
0.330
 Why?
Retrospective Studies
40
2022
16937
0.320
 Why?
Societies, Medical
7
2021
865
0.300
 Why?
Melanoma
5
2018
813
0.300
 Why?
Whole-Body Irradiation
1
2009
78
0.300
 Why?
Pulmonary Ventilation
4
2021
84
0.300
 Why?
Guidelines as Topic
2
2020
270
0.300
 Why?
Chemotherapy, Adjuvant
12
2017
417
0.300
 Why?
Karnofsky Performance Status
11
2020
37
0.290
 Why?
Protein Kinase Inhibitors
4
2021
1003
0.290
 Why?
ErbB Receptors
8
2022
630
0.290
 Why?
Guideline Adherence
4
2018
569
0.290
 Why?
Medical Oncology
7
2021
332
0.280
 Why?
Quinazolines
6
2014
266
0.280
 Why?
Dose-Response Relationship, Radiation
11
2019
140
0.280
 Why?
Iodine Radioisotopes
6
2006
138
0.280
 Why?
Lung
9
2021
4190
0.270
 Why?
Re-Irradiation
2
2018
9
0.270
 Why?
Controlled Clinical Trials as Topic
1
2007
28
0.270
 Why?
Radiopharmaceuticals
5
2014
192
0.260
 Why?
Breast Neoplasms
9
2020
2517
0.260
 Why?
Neoplasm Metastasis
8
2019
706
0.260
 Why?
Disease Progression
13
2018
2881
0.260
 Why?
Follow-Up Studies
22
2018
5350
0.250
 Why?
Anticonvulsants
2
2019
232
0.250
 Why?
Tumor Burden
9
2017
321
0.240
 Why?
Biomarkers, Tumor
6
2021
1334
0.230
 Why?
Paclitaxel
5
2011
256
0.230
 Why?
Proto-Oncogene Proteins B-raf
2
2017
230
0.220
 Why?
Tomography, X-Ray Computed
10
2018
2798
0.220
 Why?
Prospective Studies
22
2018
7947
0.220
 Why?
Spinal Cord
4
2018
381
0.220
 Why?
Steroids
2
2019
162
0.210
 Why?
Taxoids
5
2015
118
0.210
 Why?
Carcinoma
1
2006
231
0.200
 Why?
Lymphatic Metastasis
3
2017
337
0.200
 Why?
Central Nervous System
2
2017
282
0.200
 Why?
Carcinoma, Renal Cell
3
2018
234
0.190
 Why?
Gastrointestinal Neoplasms
3
2019
78
0.190
 Why?
Carcinoma, Hepatocellular
2
2005
373
0.190
 Why?
Magnetic Resonance Imaging
9
2019
3861
0.190
 Why?
Radiography
8
2014
839
0.180
 Why?
Necrosis
3
2019
245
0.180
 Why?
Medical Illustration
2
2012
10
0.180
 Why?
Randomized Controlled Trials as Topic
7
2021
1701
0.180
 Why?
Organs at Risk
2
2012
36
0.180
 Why?
Ribs
2
2012
34
0.180
 Why?
Positron Emission Tomography Computed Tomography
2
2020
117
0.170
 Why?
Brachial Plexus
2
2012
35
0.170
 Why?
Professional Staff Committees
4
2001
11
0.170
 Why?
Oligodendroglioma
4
2014
15
0.170
 Why?
Esophagectomy
1
2002
135
0.160
 Why?
Testicular Neoplasms
1
2022
112
0.160
 Why?
Neoplasms
6
2020
2929
0.160
 Why?
Mutation
4
2021
4132
0.160
 Why?
Peptide Fragments
4
1989
706
0.160
 Why?
Research Design
7
2018
1128
0.160
 Why?
Proportional Hazards Models
8
2020
1307
0.150
 Why?
Thymus Neoplasms
2
2017
28
0.150
 Why?
Thymoma
2
2017
36
0.150
 Why?
Hippocampus
1
2025
969
0.150
 Why?
Consolidation Chemotherapy
1
2019
10
0.150
 Why?
Esophagus
2
2012
259
0.150
 Why?
Metalloporphyrins
3
2011
101
0.150
 Why?
Meningeal Neoplasms
3
2017
94
0.150
 Why?
Maximum Tolerated Dose
6
2010
213
0.150
 Why?
Congresses as Topic
2
2019
225
0.150
 Why?
Quality of Life
6
2025
3165
0.150
 Why?
Time Factors
10
2019
7107
0.150
 Why?
Radiation Injuries
5
2015
149
0.150
 Why?
Expert Testimony
1
2019
43
0.140
 Why?
Watchful Waiting
1
2019
87
0.140
 Why?
Aquaporin 4
1
2019
98
0.140
 Why?
Gray Matter
1
2019
89
0.140
 Why?
Intracranial Arteriovenous Malformations
2
1995
52
0.130
 Why?
Spinal Neoplasms
1
2018
37
0.130
 Why?
CTLA-4 Antigen
1
2018
107
0.130
 Why?
Intersectoral Collaboration
1
2018
62
0.130
 Why?
Carboplatin
4
2011
161
0.130
 Why?
Endpoint Determination
1
2018
83
0.130
 Why?
Treatment Failure
5
2014
364
0.130
 Why?
Kidney Neoplasms
3
2018
413
0.130
 Why?
Professional Competence
1
2018
97
0.130
 Why?
Cognition
4
2013
1262
0.130
 Why?
Genes, ras
1
2017
96
0.130
 Why?
Decision Trees
1
1997
81
0.130
 Why?
Triazines
2
2009
49
0.120
 Why?
Pituitary Neoplasms
5
1994
191
0.120
 Why?
Proto-Oncogene Proteins c-kit
1
2017
72
0.120
 Why?
Antineoplastic Agents, Immunological
1
2019
199
0.120
 Why?
Interdisciplinary Communication
1
2018
201
0.120
 Why?
Mortality
1
2019
364
0.120
 Why?
Hemangioma, Cavernous
2
1993
14
0.120
 Why?
Fluorouracil
6
2004
237
0.120
 Why?
Salvage Therapy
4
2017
157
0.120
 Why?
Brain
5
2019
2934
0.120
 Why?
Antibodies
1
2018
402
0.120
 Why?
Programmed Cell Death 1 Receptor
1
2018
273
0.120
 Why?
Cohort Studies
7
2019
5898
0.120
 Why?
Pulmonary Atelectasis
1
2015
16
0.120
 Why?
Age Factors
8
2017
3311
0.120
 Why?
Adrenal Cortex Hormones
1
2019
501
0.120
 Why?
Accreditation
2
2013
98
0.110
 Why?
Patient Preference
1
2018
220
0.110
 Why?
Radiation-Sensitizing Agents
5
2009
43
0.110
 Why?
Medically Underserved Area
1
2016
100
0.110
 Why?
Antineoplastic Agents, Phytogenic
2
2006
179
0.110
 Why?
Radiographic Image Interpretation, Computer-Assisted
1
2015
121
0.110
 Why?
Postoperative Care
1
2017
283
0.110
 Why?
United States
13
2022
15723
0.110
 Why?
Central Nervous System Neoplasms
1
2017
173
0.110
 Why?
Carmustine
7
2010
52
0.100
 Why?
Analysis of Variance
5
2014
1309
0.100
 Why?
Risk Assessment
3
2021
3580
0.100
 Why?
Perfusion Imaging
1
2014
64
0.100
 Why?
Fibrosarcoma
1
1993
23
0.100
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
22
0.100
 Why?
Camptothecin
2
2011
140
0.100
 Why?
Triple Negative Breast Neoplasms
1
2017
220
0.100
 Why?
Receptors, Progesterone
4
2020
353
0.100
 Why?
Contraindications
2
2008
84
0.100
 Why?
Nelson Syndrome
4
1987
5
0.100
 Why?
Cerebellar Neoplasms
2
1996
177
0.100
 Why?
Medulloblastoma
2
1996
215
0.100
 Why?
Adolescent
22
2017
22396
0.100
 Why?
Kaplan-Meier Estimate
5
2019
960
0.100
 Why?
Respiratory Function Tests
1
2015
572
0.100
 Why?
Disease-Free Survival
6
2014
772
0.100
 Why?
Pyrazoles
2
2014
501
0.100
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1498
0.090
 Why?
beta-Endorphin
3
1989
4
0.090
 Why?
Pyridines
2
2014
616
0.090
 Why?
Radiotherapy, High-Energy
4
2000
18
0.090
 Why?
Particle Accelerators
1
1991
9
0.090
 Why?
Adrenocorticotropic Hormone
3
1989
147
0.090
 Why?
Bone Neoplasms
3
2007
252
0.090
 Why?
Radiation Protection
2
2009
38
0.090
 Why?
Pancreatic Neoplasms
1
2000
943
0.080
 Why?
Quality Assurance, Health Care
3
2009
314
0.080
 Why?
Forced Expiratory Volume
2
2015
493
0.080
 Why?
Hyperthermia, Induced
1
1992
121
0.080
 Why?
Young Adult
8
2017
14033
0.080
 Why?
Technology, Radiologic
1
2010
6
0.080
 Why?
Radiotherapy, Computer-Assisted
1
2010
12
0.080
 Why?
Bevacizumab
3
2015
168
0.080
 Why?
MEDLINE
1
2009
20
0.080
 Why?
Databases, Factual
5
2017
1474
0.080
 Why?
Spine
1
1991
181
0.080
 Why?
Clinical Trials, Phase II as Topic
2
2002
78
0.080
 Why?
Multivariate Analysis
6
2020
1510
0.080
 Why?
Neurosurgery
1
2009
41
0.080
 Why?
Severity of Illness Index
2
2008
2940
0.070
 Why?
Adrenal Medulla
1
1989
9
0.070
 Why?
Adenoma
4
1994
218
0.070
 Why?
Neurotensin
1
1989
13
0.070
 Why?
Drug Therapy
1
2009
81
0.070
 Why?
Risk Factors
7
2021
10672
0.070
 Why?
Fractures, Spontaneous
1
1988
16
0.070
 Why?
Meta-Analysis as Topic
1
2009
170
0.070
 Why?
Piperidines
1
2010
219
0.070
 Why?
Ependymoma
2
2009
176
0.070
 Why?
Catheter Ablation
1
2012
351
0.070
 Why?
Esophageal Fistula
2
2000
21
0.070
 Why?
Equipment Failure Analysis
1
2009
130
0.070
 Why?
Liver
2
2008
1853
0.070
 Why?
Imaging, Three-Dimensional
2
2010
586
0.070
 Why?
Pheochromocytoma
1
1989
58
0.070
 Why?
Humeral Fractures
1
1988
46
0.070
 Why?
Radionuclide Imaging
1
2008
114
0.070
 Why?
Education, Medical, Graduate
1
2013
553
0.070
 Why?
Respiratory Mechanics
1
2008
74
0.070
 Why?
Adrenal Gland Neoplasms
1
1989
90
0.070
 Why?
Lymph Node Excision
1
2009
174
0.070
 Why?
Positron-Emission Tomography
2
2008
320
0.070
 Why?
Femoral Fractures
1
1988
83
0.070
 Why?
Craniopharyngioma
1
2009
78
0.070
 Why?
Chromatography, Gel
4
1989
129
0.070
 Why?
Palliative Care
5
2018
992
0.070
 Why?
Surveys and Questionnaires
2
2018
6052
0.060
 Why?
Kidney
2
2005
1496
0.060
 Why?
Pulmonary Disease, Chronic Obstructive
1
2015
1080
0.060
 Why?
Statistics, Nonparametric
2
2018
432
0.060
 Why?
Radioimmunoassay
4
1989
167
0.060
 Why?
Vascular Diseases
1
2009
251
0.060
 Why?
Genetic Markers
2
2017
338
0.060
 Why?
Whole Body Imaging
1
2006
26
0.060
 Why?
Uterine Cervical Neoplasms
1
1989
275
0.060
 Why?
Hepatitis B, Chronic
1
2005
19
0.060
 Why?
Biomedical Research
2
2009
716
0.060
 Why?
Seizures
1
2009
458
0.060
 Why?
Neoplasm Grading
2
2020
309
0.060
 Why?
Linear Models
3
2017
860
0.060
 Why?
Drug Administration Schedule
3
2014
779
0.060
 Why?
Strontium Radioisotopes
2
2006
3
0.060
 Why?
Vascular Endothelial Growth Factor A
1
2008
561
0.060
 Why?
Diagnostic Imaging
3
2009
334
0.060
 Why?
Databases as Topic
1
2005
68
0.060
 Why?
Gene Rearrangement
2
2018
156
0.060
 Why?
Clinical Competence
1
2013
1238
0.060
 Why?
Consensus
2
2021
482
0.060
 Why?
Delivery of Health Care
1
2012
949
0.060
 Why?
Hemoglobins
1
2007
376
0.060
 Why?
Antiemetics
1
2005
50
0.060
 Why?
Pituitary Hormones
1
1984
16
0.050
 Why?
Organ Size
1
2005
473
0.050
 Why?
Peptides
3
1985
1002
0.050
 Why?
Immunotherapy
2
2022
672
0.050
 Why?
Physicians
1
2013
936
0.050
 Why?
Body Fluids
1
1985
71
0.050
 Why?
Retreatment
3
2012
76
0.050
 Why?
Anticoagulants
1
2009
721
0.050
 Why?
Cognition Disorders
2
2010
542
0.050
 Why?
Age Distribution
1
2005
396
0.050
 Why?
Dexamethasone
3
2012
373
0.050
 Why?
Sex Distribution
1
2005
381
0.050
 Why?
Practice Patterns, Physicians'
1
2013
1332
0.050
 Why?
Hepatitis C, Chronic
1
2005
133
0.050
 Why?
Regression Analysis
2
2017
1003
0.050
 Why?
Erlotinib Hydrochloride
2
2014
72
0.050
 Why?
Liver Cirrhosis
1
2005
271
0.050
 Why?
Feasibility Studies
3
2011
1086
0.050
 Why?
Propionates
1
2003
39
0.050
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2006
258
0.050
 Why?
Chromatography, Affinity
3
1989
88
0.050
 Why?
Preoperative Care
1
2005
379
0.050
 Why?
Internship and Residency
1
2013
1261
0.050
 Why?
Aniline Compounds
1
2003
119
0.050
 Why?
Societies
1
2022
38
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2004
118
0.040
 Why?
Pterygium
1
2000
4
0.040
 Why?
Organizational Objectives
4
2001
65
0.040
 Why?
Algorithms
2
2017
1848
0.040
 Why?
Ontario
2
2017
94
0.040
 Why?
Esophagoscopy
1
2002
218
0.040
 Why?
Neurologic Examination
1
2000
129
0.040
 Why?
Reproducibility of Results
2
2015
3411
0.040
 Why?
Vincristine
2
2010
140
0.040
 Why?
B7-H1 Antigen
1
2022
247
0.040
 Why?
BRCA1 Protein
1
2020
83
0.040
 Why?
Carcinoma, Bronchogenic
1
1999
20
0.040
 Why?
Spinal Cord Neoplasms
1
1999
40
0.040
 Why?
Carcinoma, Large Cell
1
1999
17
0.040
 Why?
Neuropsychological Tests
3
2013
1124
0.040
 Why?
Receptors, Estrogen
2
2013
470
0.040
 Why?
Medical Records
2
2010
183
0.040
 Why?
Liver Transplantation
1
2005
792
0.040
 Why?
Reoperation
2
2012
614
0.030
 Why?
Urinary Bladder Neoplasms
1
2001
253
0.030
 Why?
Estrogens
1
2020
381
0.030
 Why?
Thoracic Vertebrae
1
2018
79
0.030
 Why?
Iridium Radioisotopes
1
1997
4
0.030
 Why?
Epidemiologic Methods
1
2017
92
0.030
 Why?
Aziridines
2
1994
6
0.030
 Why?
Clinical Trials, Phase I as Topic
1
1997
52
0.030
 Why?
Colorado
3
2014
4605
0.030
 Why?
Child, Preschool
7
2009
11740
0.030
 Why?
Molecular Weight
2
1989
325
0.030
 Why?
Biopsy, Needle
1
2017
184
0.030
 Why?
Skin Neoplasms
2
2017
863
0.030
 Why?
Esophagitis
2
2009
67
0.030
 Why?
Benzoquinones
2
1994
47
0.030
 Why?
Memory Disorders
2
2010
195
0.030
 Why?
Respiration
1
2017
209
0.030
 Why?
Supratentorial Neoplasms
1
1996
18
0.030
 Why?
Odds Ratio
1
1999
1058
0.030
 Why?
Neutropenia
2
2009
156
0.030
 Why?
Precision Medicine
1
2020
463
0.030
 Why?
Heart
1
2020
635
0.030
 Why?
Meningioma
1
1997
87
0.030
 Why?
Propensity Score
1
2018
364
0.030
 Why?
Sex Factors
2
2014
2090
0.030
 Why?
Estrogen Receptor alpha
1
2017
161
0.030
 Why?
Cerebral Angiography
1
1995
118
0.030
 Why?
Forecasting
3
2001
390
0.030
 Why?
Pilot Projects
3
2015
1873
0.030
 Why?
Marital Status
1
2014
47
0.030
 Why?
Myocardium
1
2020
949
0.030
 Why?
Technetium Tc 99m Pentetate
1
2014
7
0.030
 Why?
Ventilation-Perfusion Ratio
1
2014
12
0.030
 Why?
Nuclear Medicine
1
2014
9
0.030
 Why?
Vital Capacity
1
2015
312
0.030
 Why?
Radioisotope Teletherapy
1
1993
2
0.030
 Why?
Cobalt Radioisotopes
1
1993
7
0.030
 Why?
Patient Safety
1
2017
339
0.030
 Why?
Nervous System Diseases
1
1997
281
0.030
 Why?
Molecular Targeted Therapy
1
2017
441
0.030
 Why?
Texas
1
2014
278
0.030
 Why?
Spatial Analysis
1
2013
23
0.030
 Why?
SEER Program
1
2014
225
0.020
 Why?
Child
9
2009
22620
0.020
 Why?
Vimentin
1
1993
54
0.020
 Why?
Developing Countries
1
2016
315
0.020
 Why?
Radiodermatitis
1
1993
11
0.020
 Why?
Prostatic Neoplasms
1
2001
977
0.020
 Why?
Radiometry
1
2013
55
0.020
 Why?
Monte Carlo Method
1
2013
155
0.020
 Why?
Observer Variation
1
2014
353
0.020
 Why?
Scalp
1
1993
38
0.020
 Why?
Cerebral Cortex
1
1996
467
0.020
 Why?
Protein-Tyrosine Kinases
1
2016
436
0.020
 Why?
Time
1
2013
88
0.020
 Why?
Mitosis
1
1993
202
0.020
 Why?
Medical Errors
1
2013
120
0.020
 Why?
Radiation Dosage
1
2013
190
0.020
 Why?
Remission Induction
2
2008
310
0.020
 Why?
Ascorbic Acid
1
1993
181
0.020
 Why?
Disease Management
1
2016
639
0.020
 Why?
Radiology
1
2014
176
0.020
 Why?
International Agencies
1
2011
31
0.020
 Why?
Diagnosis, Differential
1
2015
1504
0.020
 Why?
Breast Neoplasms, Male
1
2011
29
0.020
 Why?
Electrons
1
1991
88
0.020
 Why?
Bronchography
1
2010
10
0.020
 Why?
Fibrosis
1
2013
548
0.020
 Why?
Infusions, Intravenous
2
2004
427
0.020
 Why?
Sensitivity and Specificity
1
2015
1987
0.020
 Why?
Procarbazine
1
1990
9
0.020
 Why?
Lomustine
1
1990
14
0.020
 Why?
Longitudinal Studies
1
2018
2971
0.020
 Why?
Cell Nucleus
1
1993
619
0.020
 Why?
Physics
1
2010
17
0.020
 Why?
Selection Bias
1
2009
38
0.020
 Why?
Clinical Trials Data Monitoring Committees
1
2009
3
0.020
 Why?
Neoplasm, Residual
1
2010
139
0.020
 Why?
Hypophysectomy
1
1989
15
0.020
 Why?
Smoking
1
2017
1557
0.020
 Why?
Quality Control
1
2010
165
0.020
 Why?
Immunohistochemistry
1
1993
1734
0.020
 Why?
Chromatin
1
1993
557
0.020
 Why?
Platinum
1
2009
50
0.020
 Why?
Incidence
1
2016
2865
0.020
 Why?
Adrenal Cortex
1
1989
33
0.020
 Why?
Prevalence
1
2016
2830
0.020
 Why?
Hepatic Veno-Occlusive Disease
1
2008
12
0.020
 Why?
Neoplasms, Unknown Primary
1
1988
20
0.020
 Why?
Bronchi
1
2010
270
0.020
 Why?
beta-Lipotropin
2
1985
2
0.020
 Why?
Prostheses and Implants
1
2010
141
0.020
 Why?
Certification
1
2010
119
0.020
 Why?
Liver Regeneration
1
2008
47
0.020
 Why?
Endorphins
2
1985
9
0.020
 Why?
Polymorphism, Single Nucleotide
1
2016
2186
0.020
 Why?
Epinephrine
1
1989
154
0.020
 Why?
Anti-Inflammatory Agents
1
2012
483
0.020
 Why?
Motion
1
2008
100
0.020
 Why?
Fracture Fixation, Intramedullary
1
1988
60
0.020
 Why?
Administration, Oral
1
2010
844
0.020
 Why?
International Cooperation
1
2008
197
0.020
 Why?
Mental Status Schedule
1
2007
34
0.020
 Why?
Reference Values
1
1989
807
0.020
 Why?
Creatinine
1
1989
492
0.020
 Why?
Infant
4
1999
9987
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2411
0.020
 Why?
Bleomycin
1
2009
260
0.020
 Why?
Rectal Neoplasms
1
2008
156
0.020
 Why?
Predictive Value of Tests
2
2008
2103
0.020
 Why?
Chromatography, High Pressure Liquid
1
1989
593
0.020
 Why?
Southwestern United States
1
2006
95
0.020
 Why?
California
1
2008
467
0.020
 Why?
Neovascularization, Pathologic
1
2008
290
0.020
 Why?
Chromium Compounds
1
2006
2
0.020
 Why?
Polycythemia Vera
1
2006
8
0.020
 Why?
Sodium Iodide
1
2006
3
0.020
 Why?
Pleural Effusion, Malignant
1
2006
12
0.010
 Why?
Hydrocephalus
1
1987
111
0.010
 Why?
Glucocorticoids
1
2010
540
0.010
 Why?
Hyperthyroidism
1
2006
21
0.010
 Why?
Patient Isolation
1
2006
20
0.010
 Why?
Ascites
1
2006
47
0.010
 Why?
Methadone
1
1987
109
0.010
 Why?
Yttrium Radioisotopes
1
2006
63
0.010
 Why?
DNA Repair
1
2008
257
0.010
 Why?
DNA Damage
1
2008
436
0.010
 Why?
Concanavalin A
1
1985
71
0.010
 Why?
Chromatography
1
1985
27
0.010
 Why?
Organophosphorus Compounds
1
2006
84
0.010
 Why?
Phosphates
1
2006
179
0.010
 Why?
ACTH Syndrome, Ectopic
1
1984
1
0.010
 Why?
Occipital Lobe
1
2004
26
0.010
 Why?
Organometallic Compounds
1
2006
115
0.010
 Why?
Lymphoma, Non-Hodgkin
1
2006
125
0.010
 Why?
Biotransformation
1
1984
62
0.010
 Why?
Carbohydrate Metabolism
1
1984
61
0.010
 Why?
Brain Edema
1
2004
62
0.010
 Why?
Patient Education as Topic
1
2010
796
0.010
 Why?
Arginine Vasopressin
1
1984
44
0.010
 Why?
Thrombocytopenia
1
2006
208
0.010
 Why?
Recurrence
2
2000
1125
0.010
 Why?
Genomics
1
2009
836
0.010
 Why?
Vomiting
1
2004
131
0.010
 Why?
Corticotropin-Releasing Hormone
1
1984
72
0.010
 Why?
Oils
1
1983
22
0.010
 Why?
Motor Skills
1
2004
106
0.010
 Why?
Bipolar Disorder
1
1985
256
0.010
 Why?
Thyroid Neoplasms
1
2006
346
0.010
 Why?
Immunologic Factors
1
2003
256
0.010
 Why?
Pain
1
2006
779
0.010
 Why?
Antimetabolites, Antineoplastic
1
2001
108
0.010
 Why?
Psychometrics
1
2004
733
0.010
 Why?
Postoperative Period
1
2000
354
0.010
 Why?
Apoptosis
1
2008
2454
0.010
 Why?
Thorax
1
1999
51
0.010
 Why?
Opioid-Related Disorders
1
1987
583
0.010
 Why?
Michigan
1
1999
135
0.010
 Why?
Cysts
1
1999
111
0.010
 Why?
Bias
1
1999
205
0.010
 Why?
Antibodies, Monoclonal
1
2006
1524
0.010
 Why?
Mercaptopurine
1
1996
15
0.010
 Why?
Mitomycin
1
1996
33
0.010
 Why?
Meninges
1
1997
49
0.010
 Why?
Biopsy
1
1999
1071
0.010
 Why?
Cross-Sectional Studies
1
2007
5809
0.010
 Why?
Autoantibodies
1
1983
1498
0.010
 Why?
Cause of Death
1
1996
461
0.010
 Why?
Decision Making
1
2001
970
0.010
 Why?
Solutions
1
1993
166
0.010
 Why?
Neoplasms, Radiation-Induced
1
1993
98
0.010
 Why?
Cerebral Hemorrhage
1
1993
119
0.010
 Why?
Computer Simulation
1
1995
1035
0.010
 Why?
Patient Compliance
1
1994
614
0.000
 Why?
Evaluation Studies as Topic
1
1989
169
0.000
 Why?
Double-Blind Method
1
1993
2030
0.000
 Why?
Melanocyte-Stimulating Hormones
1
1985
3
0.000
 Why?
Lithium
1
1985
41
0.000
 Why?
Postoperative Complications
1
1996
2934
0.000
 Why?
Brassica
1
1983
5
0.000
 Why?
Spain
1
1983
49
0.000
 Why?
Antigen-Antibody Complex
1
1983
72
0.000
 Why?
Drug Synergism
1
1984
364
0.000
 Why?
Syndrome
1
1983
377
0.000
 Why?
In Vitro Techniques
1
1984
1057
0.000
 Why?
Sheep
1
1984
874
0.000
 Why?
Animals
1
1984
38331
0.000
 Why?
Gaspar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (490) concept(s)
_
Co-Authors Expand Description
See all (35) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)